Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06216535 · ClinicalTrials.gov registry record · Phase 2

Escitalopram in Asthma Patients With Frequent Exacerbation

A Phase 2 study of Asthma, sponsored by University of Texas Southwestern Medical Center.

Recruiting
Registry status
Phase 2
Development phase
105
Enrollment target
1
Study location

NCT06216535 is a Phase 2 study of Asthma that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 105 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06216535, a Phase 2 study of Asthma, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.

RECRUITING
Registry status
Phase 2
Development phase
105 participants
Enrollment target
1
Study location

Study Summary

Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), such as escitalopram are widely used for mood and anxiety disorders. However, they have also been explored, with promising findings, for a variety of disorders outside of psychiatry. Clinical studies of SSRIs in depressed people with asthma were associated with decreased asthma exacerbations and improvement in asthma control. In this study, the number of asthma exacerbations will be assessed as the primary outcome measure in patients using escitalopram vs. placebo.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Escitalopram

Study Locations (1)

Texas

  • UT Southwestern, 1440 Empire Central, Ste. LD4.100 - Dallas

Trial Details

FieldValue
Enrollment Target 105 participants
Start Date 2025-05-19
Est. Completion 2029-06-01
Phase Phase 2

What the Registry Record Tells You About NCT06216535

The ClinicalTrials.gov registry entry for NCT06216535 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (93% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06216535 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT06216535 about?

NCT06216535 is a clinical study titled "Escitalopram in Asthma Patients With Frequent Exacerbation". Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), such as escitalopram are widely used for mood and anxiety disorders. However, they have also been explored, with promising findings, for a variety of disorders outside of psychiatry. Clinical studies of SSRIs in depressed...

What is the current status of trial NCT06216535?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2025-05-19. Estimated completion is 2029-06-01.

What conditions does trial NCT06216535 study?

This clinical trial studies the following conditions: Asthma.

What interventions are being tested in trial NCT06216535?

The interventions under investigation include: Placebo (DRUG), Escitalopram (DRUG).

Who is sponsoring clinical trial NCT06216535?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06216535 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.